Balance Sheet
Cash Flow Statement
AmortizationAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Dr Reddys Laboratories (RDY) Other financing activities (2016 - 2025)

Historic Other financing activities for Dr Reddys Laboratories (RDY) over the last 17 years, with Q3 2025 value amounting to $18.8 million.

  • Dr Reddys Laboratories' Other financing activities rose 497.9% to $18.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $18.8 million, marking a year-over-year increase of 497.9%. This contributed to the annual value of $19.4 million for FY2025, which is 664.56% up from last year.
  • Dr Reddys Laboratories' Other financing activities amounted to $18.8 million in Q3 2025, which was up 497.9% from -$14.1 million recorded in Q2 2025.
  • In the past 5 years, Dr Reddys Laboratories' Other financing activities registered a high of $114.4 million during Q2 2024, and its lowest value of -$168.8 million during Q4 2023.
  • Its 5-year average for Other financing activities is -$23.6 million, with a median of $12.5 million in 2022.
  • Per our database at Business Quant, Dr Reddys Laboratories' Other financing activities plummeted by 247647.53% in 2023 and then soared by 73663.98% in 2024.
  • Over the past 5 years, Dr Reddys Laboratories' Other financing activities (Quarter) stood at -$34.3 million in 2021, then skyrocketed by 120.72% to $7.1 million in 2022, then crashed by 2476.48% to -$168.8 million in 2023, then soared by 110.59% to $17.9 million in 2024, then grew by 4.98% to $18.8 million in 2025.
  • Its Other financing activities stands at $18.8 million for Q3 2025, versus -$14.1 million for Q2 2025 and $19.0 million for Q1 2025.